Australia markets closed


Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
1.4800-0.0300 (-1.99%)
As of 01:05PM CEST. Market open.
Full screen
Previous close1.5100
Bid1.3700 x N/A
Ask1.5600 x N/A
Day's range1.4800 - 1.4800
52-week range0.2660 - 8.0250
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Synlogic Reports First Quarter 2024 Financial Results

    CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored

  • Simply Wall St.

    We Think Synlogic (NASDAQ:SYBX) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Zacks

    Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates

    Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?